{
 "query": "lebrikizumab",
 "ingredient": "lebrikizumab",
 "slug": "lebrikizumab",
 "rxcui": "2693758",
 "brands": [],
 "names": [
  "lebrikizumab"
 ],
 "classes": [
  {
   "id": "D11AH",
   "name": "Agents for dermatitis, excluding corticosteroids"
  }
 ],
 "alternatives": [
  "abrocitinib",
  "alitretinoin",
  "crisaborole",
  "cromolyn",
  "delgocitinib",
  "dupilumab",
  "nemolizumab",
  "pimecrolimus",
  "ruxolitinib",
  "tacrolimus",
  "tralokinumab"
 ],
 "label": {},
 "faers": {
  "total": 180,
  "serious": 113,
  "death": 2,
  "hospitalization": 45,
  "primary_suspect": 180,
  "top_reactions": [
   [
    "Dermatitis Atopic",
    17
   ],
   [
    "Conjunctivitis",
    15
   ],
   [
    "Drug Ineffective",
    11
   ],
   [
    "Rash",
    11
   ],
   [
    "Erythema",
    10
   ],
   [
    "Treatment Failure",
    9
   ],
   [
    "Arthralgia",
    8
   ],
   [
    "Asthma",
    7
   ],
   [
    "Eosinophilia",
    7
   ],
   [
    "Injection Site Pain",
    7
   ],
   [
    "Off Label Use",
    7
   ],
   [
    "Pruritus",
    7
   ],
   [
    "Skin Exfoliation",
    7
   ],
   [
    "Dry Skin",
    6
   ],
   [
    "Eczema",
    6
   ]
  ],
  "by_year": {
   "2018": 1,
   "2019": 6,
   "2021": 2,
   "2022": 1,
   "2023": 1,
   "2024": 22,
   "2025": 79,
   "2026": 63
  },
  "by_year_primary": {
   "2018": 1,
   "2019": 6,
   "2021": 2,
   "2022": 1,
   "2023": 1,
   "2024": 22,
   "2025": 79,
   "2026": 63
  }
 },
 "faers_base": {
  "total": 20692304,
  "serious_share": 0.5742697381596559,
  "death_share": 0.09102355155810585
 },
 "recalls": [],
 "recall_total": 0,
 "drugsfda": {
  "applications": 0,
  "nda": 0,
  "anda": 0,
  "first_approval": "",
  "rems": false,
  "rems_last": "",
  "labeling_supplements": 0,
  "labeling_recent": 0,
  "sponsors": [],
  "unapproved": false,
  "first_approval_fmt": ""
 },
 "trials": {
  "total": 57,
  "completed": 35,
  "terminated": 2,
  "with_results": 21,
  "industry": 51,
  "phase3": 27,
  "results_share": 0.6,
  "terminated_share": 0.03508771929824561
 },
 "pubmed": {
  "rct": 34,
  "meta": 5,
  "recent_rct": 24,
  "cochrane": []
 },
 "payments": {
  "year": "2024",
  "usd": 0.0,
  "records": 0,
  "by_name": [],
  "names_checked": [
   "lebrikizumab"
  ],
  "source": "bulk-index"
 },
 "partd": null,
 "mdl": [],
 "dsc": [],
 "settlements": [],
 "prescrire": null,
 "eml": {
  "listed": false,
  "status": "",
  "name": "",
  "matched": null,
  "stewardship": []
 },
 "exposure": null,
 "scores": {
  "safety": {
   "score": 100,
   "letter": "A",
   "why": [],
   "weight": 0.35
  },
  "evidence": {
   "score": 44,
   "letter": "F",
   "why": [
    "34 randomized trials and 5 systematic reviews/meta-analyses indexed in PubMed",
    "No Cochrane review found (-5)"
   ],
   "weight": 0.25
  },
  "regulatory": {
   "score": 100,
   "letter": "A",
   "why": [
    "No recalls on record since 2016"
   ],
   "weight": 0.15
  },
  "conflict": {
   "score": 100,
   "letter": "A",
   "why": [
    "Pharma paid doctors $0 tied to this drug last year: negligible",
    "Not named in any pending federal MDL"
   ],
   "weight": 0.15
  },
  "options": {
   "score": 70,
   "letter": "C",
   "why": [
    "No generic version approved: brand-only pricing (-30)",
    "11 same-class alternatives exist"
   ],
   "weight": 0.1
  }
 },
 "total": 83,
 "grade": "B",
 "questions": [
  "The most-reported problems in FDA's adverse event data are dermatitis atopic, conjunctivitis, rash. How would we recognize and handle those?",
  "Why this one over abrocitinib, alitretinoin, crisaborole? What would make you pick one of those instead?",
  "There is no generic. Is there an older generic in the same class that works as well for my situation?",
  "What result are we expecting, by when, and what is the plan if it does not happen?",
  "If 100 people like me took this drug, how many would actually get better because of it, and how many would be harmed by it? (Doctors call these the number needed to treat and the number needed to harm.)"
 ]
}